Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Akoya Biosciences, Inc.

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. 

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels, PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.

View our open job descriptions: www.akoyabio.com/careers

Follow us on Twitter: www.twitter.com/AkoyaBio   

Subscribe to our YouTube channel: www.youtube.com/c/AkoyaBiosciences 

Innovatus Capital Partners

Telegraph Hill Partners

Piper Jaffray Merchant Banking

Thomas Schnettler

We are excited to welcome Crown Bioscience as an Akoya-qualified service provider! Headquartered in San Diego, CA, Crown Bioscience aims to support drug discovery through translational research across oncology and immuno-oncology.

By joining our Contract Research Organization Network, Crown Bioscience will utilize Akoya's Phenomager HT platform to offer advanced multispectral imaging technology, easily integrated into high-throughput workflows to accommodate projects regardless of scale.

Explore Crown Bioscience's digital pathology technologies: https://bit.ly/3T0ALxY

#oncology #immunooncology #drugdiscovery #phenoimager #crownbioscience

This groundbreaking study, published in Nature using our PhenoImager HT platform, offers a fresh perspective on the pathology and heterogeneity of rheumatoid arthritis. The findings hold promise for developing innovative targeted treatments for patients with this condition. 

🙌 Kudos to the authors for their valuable contribution to understanding this debilitating, autoimmune disease without a cure!

#FridayRead #PhenoImager #AkoyaInAction #SpatialBiology #RheumatoidArthritis

Join us at the Cancer Neuroscience Symposium at the MD Anderson Cancer Center in Houston, Texas!

The Akoya team will be there today and tomorrow and will be happy to discuss how our spatial biology solutions are making a difference in neuroscience and cancer research. 

Not attending? Explore our solutions on our website: https://bit.ly/47GvLFB

#SpatialBiology #Neuroscience #MDAnderson #CancerResearch #Immunology

Dr. Tom Lund and his team at the Integrated Pathology Unit (IPU) in London have consistently used our instruments, with the PhenoImager HT serving as a central resource in their laboratory.

The IPU, a collaborative effort between The Institute of Cancer Research and the Royal Marsden Hospital, is crucial in bridging clinical, translational, and basic research. Dr. Lund attributes the IPU's flexibility to their tissue-agnostic Akoya technology, which requires minimal tissue-specific optimization, allowing seamless adaptation to diverse research requirements.

We are thankful for Dr. Lund's ongoing support of our technology. We are excited to witness his lab's advancements in further understanding and treating cancer through multiplex immunofluorescence.

#spatialbiology #digitalpathology #multiplex #phenoimager SelectScience®

📢 Tomorrow is part 1 of a 2-part webinar series on fusing single-cell genomics and spatial proteomics with MaxFuse!

Hear Garry Nolan, Ph.D., discuss MaxFuse, a new AI algorithm that provides reliable, fast, and cost-effective integration of spatial proteomic data with single-cell transcriptomic and epigenomic datasets. 

This webinar will be offered at two different times on Feb 28th; attendees can join at 3 AM PT/6 AM ET/12 PM CET or 9 AM PT/12 PM ET/6 PM CET. 

Hope to see you there!

#spatialbiology #spatialproteomics #maxfuse #singlecell #genomics Genetic Engineering & Biotechnology News 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	42.24M -	42.44M 0.49%	54.92M 29.39%	74.86M 36.31%	96.63M 29.09%
cost of revenue	17.57M -	16.54M 5.91%	20.70M 25.18%	31.47M 52.03%	48.40M 53.79%
gross profit	24.66M -	25.91M 5.05%	34.22M 32.08%	43.39M 26.80%	48.24M 11.17%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	26.35M -	23.98M 8.99%	51.02M 112.73%	79.65M 56.13%	82.38M 3.42%
research and development expenses	8.76M -	9.60M 9.61%	15.70M 63.50%	23.21M 47.83%	21.89M 5.70%
other expenses	3.06M -	3.81M 24.88%	4.73M 23.88%	6.73M 42.49%	-343K 105.09%
cost and expenses	55.74M -	53.94M 3.24%	92.14M 70.84%	141.07M 53.10%	152.66M 8.22%
operating expenses	38.17M -	37.40M 2.01%	71.44M 91.02%	109.60M 53.41%	104.27M 4.86%
interest expense	1.88M -	2.72M 44.76%	3.12M 14.40%	4.55M 46.20%	8.76M 92.38%
ebitda	-10.82M -	-7.64M 29.42%	-32.91M 330.86%	-59.33M 80.29%	-47.14M 20.55%
operating income	-13.50M -	-11.49M 14.90%	-37.23M 223.92%	-66.21M 77.86%	-56.03M 15.37%
depreciation and amortization	2.68M -	3.85M 43.70%	4.32M 11.99%	6.88M 59.31%	8.89M 29.29%
total other income expenses net	-1.05M -	-5.17M 391.17%	-5.85M 13.11%	-4.31M 26.32%	-7.25M 68.24%
income before tax	-14.56M -	-16.66M 14.47%	-43.08M 158.49%	-70.52M 63.71%	-63.28M 10.26%
income tax expense	194K -	42K 78.35%	-140K 433.33%	123K 187.86%	40K 67.48%
net income	-14.75M -	-16.71M 13.25%	-42.94M 157.00%	-70.64M 64.53%	-63.32M 10.36%
weighted average shs out	28.92M -	28.92M 0%	26.90M 6.98%	37.75M 40.34%	44.43M 17.72%
weighted average shs out dil	28.92M -	28.92M 0%	26.90M 6.98%	37.75M 40.34%	44.43M 17.72%
eps	-0.51 -	-0.58 13.73%	-1.60 175.86%	-1.87 16.88%	-1.43 23.53%
epsdiluted	-0.51 -	-0.58 13.73%	-1.60 175.86%	-1.87 16.88%	-1.43 23.53%

COM:AKOYABIO

Akoya Biosciences, Inc.

Last Close

2.12

22/11 21:00

Market Cap

102.72M

Beta: -

Volume Today

81.11K

Avg: -

Preview